By Katherine Hamilton
Solid Biosciences received clearance from the Food and Drug Administration for an investigational new drug application, the company said Tuesday.
The application is for SGT-212, designed to treat the degenerative disease Friedreich's ataxia. The drug is unique because it uses two routes of administration to address the illness in the cardiac region and the cerebellum.
The Charlestown, Mass.-based company expects to initiate a phase 1b clinical trial in the second half of 2025.
Shares climbed 20% to $4.70 in after-hours trading following the news.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(MORE TO FOLLOW) Dow Jones Newswires
January 07, 2025 16:40 ET (21:40 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。